申请人:Astellas Pharma Inc.
公开号:EP2301922A1
公开(公告)日:2011-03-30
[Problems] A useful compound which can be used as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease is provided.
[Means for Solution] The present inventors have conducted extensive studies on EP4 receptor agonists, and as a result, have found that a novel pyridone compound, in which a group having an acidic group is substituted at the 1-position of the pyridone ring, the 6-position is bonded with an aromatic ring group via a linking part, and the linking part contains a nitrogen atom, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action, it is useful as a pharmaceutical, in particular, as an agent for treating peripheral arterial occlusive disease.
[问题]本发明提供了一种可用作药物的有用化合物,特别是治疗外周动脉闭塞性疾病的药物。
[解决方法]本发明人对 EP4 受体激动剂进行了广泛的研究,结果发现了一种新型吡啶酮化合物,其中具有酸性基团的基团在吡啶酮环的 1 位被取代,6 位通过连接部分与芳香环基团键合,连接部分含有氮原子,该化合物具有优异的 EP4 受体激动作用,从而完成了本发明。由于本发明的化合物具有极佳的 EP4 受体激动作用,因此可用作药物,尤其是治疗外周动脉闭塞性疾病的药物。